262 related articles for article (PubMed ID: 36809487)
1. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
Chen S; Pang J; Huang R; Xue H; Chen X
Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
[TBL] [Abstract][Full Text] [Related]
2. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants.
Liu Z; Suo C; Shi O; Lin C; Zhao R; Yuan H; Jin L; Zhang T; Chen X
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e855-e875. PubMed ID: 33387670
[TBL] [Abstract][Full Text] [Related]
3. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.
Hydes TJ; Kennedy OJ; Buchanan R; Cuthbertson DJ; Parkes J; Fraser SDS; Roderick P
BMC Med; 2023 May; 21(1):185. PubMed ID: 37198624
[TBL] [Abstract][Full Text] [Related]
4. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: Results from two prospective cohorts.
Zhang Y; Zhang T; Liu Y; Bai S; Jiang J; Zhou H; Luan J; Cao L; Lv Y; Zhang Q; Liu L; Sun S; Wang X; Zhou M; Jia Q; Song K; Zhang H; Chang Q; Fan X; Ding Y; Chen L; Zhao Y; Niu K; Xia Y
Diabetes Metab Syndr; 2023 Oct; 17(10):102873. PubMed ID: 37804689
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
8. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
9. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis.
Fan H; Liu Z; Zhang P; Wu S; Han X; Huang Y; Zhu Y; Chen X; Zhang T
Hepatol Int; 2023 Jun; 17(3):615-625. PubMed ID: 37000387
[TBL] [Abstract][Full Text] [Related]
11. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.
Liu Z; Lin C; Suo C; Zhao R; Jin L; Zhang T; Chen X
Metabolism; 2022 Feb; 127():154955. PubMed ID: 34915036
[TBL] [Abstract][Full Text] [Related]
13. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
[TBL] [Abstract][Full Text] [Related]
14. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
15. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke.
Chen S; Xue H; Huang R; Chen K; Zhang H; Chen X
Diabetes Metab; 2023 Sep; 49(5):101468. PubMed ID: 37586479
[TBL] [Abstract][Full Text] [Related]
16. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
[TBL] [Abstract][Full Text] [Related]
17. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
[TBL] [Abstract][Full Text] [Related]
18. MAFLD and CKD: An Updated Narrative Review.
Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
[TBL] [Abstract][Full Text] [Related]
19. Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study.
Ishikura K; Uemura O; Hamasaki Y; Ito S; Wada N; Hattori M; Ohashi Y; Tanaka R; Nakanishi K; Kaneko T; Honda M; ;
Nephrol Dial Transplant; 2014 Apr; 29(4):878-84. PubMed ID: 24516225
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
